{"id":"https://openalex.org/W4411047760","doi":"https://doi.org/10.1016/j.ejpb.2025.114765","title":"2-Hydroxypropyl-\u03b2-cyclodextrin, solubiliser in a novel dantrolene formulation: Its binding affinities to clinical compounds that may be used during anaesthesia or management of malignant hyperthermia","display_name":"2-Hydroxypropyl-\u03b2-cyclodextrin, solubiliser in a novel dantrolene formulation: Its binding affinities to clinical compounds that may be used during anaesthesia or management of malignant hyperthermia","publication_year":2025,"publication_date":"2025-06-05","ids":{"openalex":"https://openalex.org/W4411047760","doi":"https://doi.org/10.1016/j.ejpb.2025.114765","pmid":"https://pubmed.ncbi.nlm.nih.gov/40482975"},"language":"en","primary_location":{"id":"doi:10.1016/j.ejpb.2025.114765","doi":"https://doi.org/10.1016/j.ejpb.2025.114765","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejpb.2025.114765","pdf_url":null,"source":{"id":"https://openalex.org/S122302516","display_name":"European Journal of Pharmaceutics and Biopharmaceutics","issn_l":"0939-6411","issn":["0939-6411","1873-3441"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmaceutics and Biopharmaceutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.ejpb.2025.114765","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5086158948","display_name":"Richard Ng Kwet Shing","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210141803","display_name":"Norgine (United Kingdom)","ror":"https://ror.org/046zgtw08","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210136628","https://openalex.org/I4210141803"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Richard H. Ng Kwet Shing","raw_affiliation_strings":["Norgine Ltd, ARC Uxbridge, Building 01, Second Floor, Sanderson Road, Uxbridge UB8 1DH, UK. Electronic address: RNg@norgine.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Norgine Ltd, ARC Uxbridge, Building 01, Second Floor, Sanderson Road, Uxbridge UB8 1DH, UK. Electronic address: RNg@norgine.com","institution_ids":["https://openalex.org/I4210141803"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053560393","display_name":"David J. Wright","orcid":"https://orcid.org/0000-0003-1799-8447","observed_orcids":["https://orcid.org/0000-0003-1799-8447"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David J. Wright","raw_affiliation_strings":["Concept Life Sciences, Number Nine the BioQuarter, 9 Little France Road, Edinburgh EH16 4UX, UK. Electronic address: David.Wright@conceptlifesciences.com"],"raw_orcid":"https://orcid.org/0000-0003-1799-8447","affiliations":[{"raw_affiliation_string":"Concept Life Sciences, Number Nine the BioQuarter, 9 Little France Road, Edinburgh EH16 4UX, UK. Electronic address: David.Wright@conceptlifesciences.com","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111594781","display_name":"Sandeep Pal","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sandeep Pal","raw_affiliation_strings":["Cheminfo Solutions Ltd, 12 Bradleys Corner, Hitchin SG4 0PR, UK. Electronic address: spal@cheminfosolutions.co.uk"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cheminfo Solutions Ltd, 12 Bradleys Corner, Hitchin SG4 0PR, UK. Electronic address: spal@cheminfosolutions.co.uk","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002784136","display_name":"Samuel L. Smith","orcid":"https://orcid.org/0000-0002-7727-526X","observed_orcids":["https://orcid.org/0000-0002-7727-526X"]},"institutions":[{"id":"https://openalex.org/I4210141803","display_name":"Norgine (United Kingdom)","ror":"https://ror.org/046zgtw08","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210136628","https://openalex.org/I4210141803"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Samuel L. Smith","raw_affiliation_strings":["Norgine Ltd, ARC Uxbridge, Building 01, Second Floor, Sanderson Road, Uxbridge UB8 1DH, UK. Electronic address: SSmith@Norgine.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Norgine Ltd, ARC Uxbridge, Building 01, Second Floor, Sanderson Road, Uxbridge UB8 1DH, UK. Electronic address: SSmith@Norgine.com","institution_ids":["https://openalex.org/I4210141803"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029374519","display_name":"Lucy B. Clayton","orcid":"https://orcid.org/0009-0002-0072-3156","observed_orcids":["https://orcid.org/0009-0002-0072-3156"]},"institutions":[{"id":"https://openalex.org/I4210141803","display_name":"Norgine (United Kingdom)","ror":"https://ror.org/046zgtw08","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210136628","https://openalex.org/I4210141803"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lucy B. Clayton","raw_affiliation_strings":["Norgine Ltd, ARC Uxbridge, Building 01, Second Floor, Sanderson Road, Uxbridge UB8 1DH, UK. Electronic address: LClayton@norgine.com"],"raw_orcid":"https://orcid.org/0009-0002-0072-3156","affiliations":[{"raw_affiliation_string":"Norgine Ltd, ARC Uxbridge, Building 01, Second Floor, Sanderson Road, Uxbridge UB8 1DH, UK. Electronic address: LClayton@norgine.com","institution_ids":["https://openalex.org/I4210141803"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077817983","display_name":"Jonathan G. Bilmen","orcid":"https://orcid.org/0000-0002-4222-2117","observed_orcids":["https://orcid.org/0000-0002-4222-2117"]},"institutions":[{"id":"https://openalex.org/I2801331674","display_name":"St James's University Hospital","ror":"https://ror.org/013s89d74","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799390153","https://openalex.org/I2801331674"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jonathan G. Bilmen","raw_affiliation_strings":["St. James' University Hospital, Clinical Science Block, Beckett Street, Leeds LS9 7TF, UK. Electronic address: jonathanbilmen@nhs.net"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St. James' University Hospital, Clinical Science Block, Beckett Street, Leeds LS9 7TF, UK. Electronic address: jonathanbilmen@nhs.net","institution_ids":["https://openalex.org/I2801331674"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5086158948"],"corresponding_institution_ids":["https://openalex.org/I4210141803"],"apc_list":{"value":4210,"currency":"USD","value_usd":4210},"apc_paid":{"value":4210,"currency":"USD","value_usd":4210},"fwci":0.3863,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.536964,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"214","issue":null,"first_page":"114765","last_page":"114765"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.8560000061988831,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.8560000061988831,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10436","display_name":"Anesthesia and Sedative Agents","score":0.051899999380111694,"subfield":{"id":"https://openalex.org/subfields/2703","display_name":"Anesthesiology and Pain Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10578","display_name":"Supramolecular Chemistry and Complexes","score":0.027799999341368675,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hydroxypropyl-beta-cyclodextrin","display_name":"hydroxypropyl-\u03b2-cyclodextrin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/dantrolene","display_name":"dantrolene","score":0.9929999709129333},{"id":"https://openalex.org/keywords/malignant-hyperthermia","display_name":"malignant hyperthermia","score":0.902999997138977},{"id":"https://openalex.org/keywords/anesthesia","display_name":"anesthesia","score":0.6909999847412109},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.609000027179718},{"id":"https://openalex.org/keywords/inclusion-complexes","display_name":"inclusion complexes","score":0.5870000123977661},{"id":"https://openalex.org/keywords/solubilization","display_name":"solubilization","score":0.6579999923706055},{"id":"https://openalex.org/keywords/rocuronium","display_name":"rocuronium","score":0.781000018119812},{"id":"https://openalex.org/keywords/vecuronium","display_name":"vecuronium","score":1.0},{"id":"https://openalex.org/keywords/remifentanyl","display_name":"remifentanyl","score":1.0},{"id":"https://openalex.org/keywords/binding-affinity","display_name":"binding affinity","score":0.7409999966621399},{"id":"https://openalex.org/keywords/isothermal-titration-calorimetry","display_name":"isothermal titration calorimetry","score":0.8539999723434448},{"id":"https://openalex.org/keywords/molecular-docking","display_name":"molecular docking","score":0.7879999876022339},{"id":"https://openalex.org/keywords/binding-free-energy","display_name":"binding free energy","score":0.578000009059906}],"concepts":[{"id":"https://openalex.org/C2781460320","wikidata":"https://www.wikidata.org/wiki/Q421274","display_name":"Dantrolene","level":3,"score":0.7619225382804871},{"id":"https://openalex.org/C2780283098","wikidata":"https://www.wikidata.org/wiki/Q4688960","display_name":"Affinities","level":2,"score":0.72059565782547},{"id":"https://openalex.org/C2779433975","wikidata":"https://www.wikidata.org/wiki/Q40417805","display_name":"Cyclodextrin","level":2,"score":0.707690417766571},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6591134071350098},{"id":"https://openalex.org/C3018795828","wikidata":"https://www.wikidata.org/wiki/Q899107","display_name":"Binding affinities","level":3,"score":0.5410585999488831},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5018064975738525},{"id":"https://openalex.org/C2778575482","wikidata":"https://www.wikidata.org/wiki/Q1585081","display_name":"Malignant hyperthermia","level":2,"score":0.4449118971824646},{"id":"https://openalex.org/C21951064","wikidata":"https://www.wikidata.org/wiki/Q899212","display_name":"Combinatorial chemistry","level":1,"score":0.4075074791908264},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.33595800399780273},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.31992262601852417},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2939985692501068},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.2714161276817322},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13232511281967163},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C519063684","wikidata":"https://www.wikidata.org/wiki/Q706","display_name":"Calcium","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000073738","descriptor_name":"2-Hydroxypropyl-beta-cyclodextrin","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D000758","descriptor_name":"Anesthesia","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000758","descriptor_name":"Anesthesia","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D003620","descriptor_name":"Dantrolene","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003620","descriptor_name":"Dantrolene","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D003620","descriptor_name":"Dantrolene","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D005079","descriptor_name":"Excipients","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008305","descriptor_name":"Malignant Hyperthermia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009125","descriptor_name":"Muscle Relaxants, Central","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D012995","descriptor_name":"Solubility","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047392","descriptor_name":"beta-Cyclodextrins","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D056004","descriptor_name":"Molecular Dynamics Simulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.ejpb.2025.114765","doi":"https://doi.org/10.1016/j.ejpb.2025.114765","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejpb.2025.114765","pdf_url":null,"source":{"id":"https://openalex.org/S122302516","display_name":"European Journal of Pharmaceutics and Biopharmaceutics","issn_l":"0939-6411","issn":["0939-6411","1873-3441"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmaceutics and Biopharmaceutics","raw_type":"journal-article"},{"id":"pmid:40482975","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40482975","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1016/j.ejpb.2025.114765","doi":"https://doi.org/10.1016/j.ejpb.2025.114765","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejpb.2025.114765","pdf_url":null,"source":{"id":"https://openalex.org/S122302516","display_name":"European Journal of Pharmaceutics and Biopharmaceutics","issn_l":"0939-6411","issn":["0939-6411","1873-3441"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmaceutics and Biopharmaceutics","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332137","display_name":"Norgine","ror":"https://ror.org/02vt89g81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":41,"referenced_works":["https://openalex.org/W19470138","https://openalex.org/W1507461428","https://openalex.org/W1549357029","https://openalex.org/W1697337825","https://openalex.org/W1969046853","https://openalex.org/W1970528096","https://openalex.org/W1985588649","https://openalex.org/W2023772978","https://openalex.org/W2037535298","https://openalex.org/W2047120941","https://openalex.org/W2067174909","https://openalex.org/W2080273051","https://openalex.org/W2095238868","https://openalex.org/W2098130169","https://openalex.org/W2106140689","https://openalex.org/W2133073150","https://openalex.org/W2147993766","https://openalex.org/W2148269081","https://openalex.org/W2160544821","https://openalex.org/W2161515375","https://openalex.org/W2168515966","https://openalex.org/W2171811869","https://openalex.org/W2489848794","https://openalex.org/W2561123886","https://openalex.org/W2783351753","https://openalex.org/W2884899686","https://openalex.org/W2960637045","https://openalex.org/W3035003544","https://openalex.org/W3092761138","https://openalex.org/W3097881467","https://openalex.org/W3118703028","https://openalex.org/W3133794207","https://openalex.org/W3181319457","https://openalex.org/W3202287440","https://openalex.org/W4247852925","https://openalex.org/W4306649977","https://openalex.org/W4381112607","https://openalex.org/W4387675550","https://openalex.org/W4392517066","https://openalex.org/W4402449070","https://openalex.org/W6679797286"],"related_works":["https://openalex.org/W2088082021","https://openalex.org/W2064223750","https://openalex.org/W4399365492","https://openalex.org/W4402449070","https://openalex.org/W2561123886","https://openalex.org/W1998748856","https://openalex.org/W2008489289","https://openalex.org/W2801810826","https://openalex.org/W4367319507","https://openalex.org/W4381112607"],"abstract_inverted_index":{"2-Hydroxypropyl-\u03b2-cyclodextrin":[0],"(HP-\u03b2-CD)":[1],"is":[2,37,234],"used":[3,172],"as":[4,24],"an":[5,25,88],"excipient":[6],"to":[7,39,76,114,149,173,226,236],"improve":[8],"the":[9,12,124,175,184,199,229],"solubility":[10],"of":[11,57,74,98,136,155,177,179,183,211,232],"highly":[13],"lipophilic":[14,70],"drug":[15],"dantrolene":[16],"in":[17,53,62,79,94,200,243],"a":[18,54,132,153],"novel":[19],"formulation,":[20],"NPJ5008.":[21],"Dantrolene":[22],"acts":[23],"antidote":[26],"for":[27,110,117],"life-threatening":[28],"anaesthesia-associated":[29],"malignant":[30],"hyperthermia":[31],"(MH)":[32],"crises":[33],"and":[34,46,108,144,192,216],"intervention":[35],"speed":[36],"essential":[38],"minimise":[40],"morbidity.":[41],"NPJ5008":[42,233],"can":[43],"be":[44],"prepared":[45],"administered":[47,84],"substantially":[48],"faster":[49],"than":[50],"DANTRIUM":[51],"IV":[52],"smaller":[55],"volume":[56],"fluid.":[58],"Like":[59],"other":[60,82,239],"cyclodextrins":[61],"clinical":[63],"use,":[64],"HP-\u03b2-CD":[65,75,99,141,151,180,230],"forms":[66],"inclusion":[67],"complexes":[68],"with":[69,81,123,140,181,208,238],"molecules.":[71],"The":[72],"potential":[73],"unintentionally":[77],"interact":[78],"vivo":[80],"drugs":[83,240],"during":[85],"anaesthesia":[86],"or":[87],"MH":[89],"emergency":[90],"was":[91,101,142,170,222],"assessed.":[92],"An":[93],"silico":[95,201],"predictive":[96],"model":[97],"binding":[100,118,225],"built":[102],"from":[103,198],"published":[104],"data":[105,116],"using":[106,131,152],"LigPrep/Glide":[107],"GROMACS":[109],"molecular":[111,125],"dynamic":[112],"simulations":[113],"generate":[115],"free":[119],"energy":[120],"calculations,":[121],"performed":[122],"mechanics":[126],"Poisson\u2013Boltzmann":[127],"surface":[128],"area":[129],"method":[130],"thermodynamic":[133],"cycle.":[134],"Docking":[135],">70":[137],"anaesthesia-relevant":[138],"compounds":[139,146],"evaluated":[143],"10":[145],"were":[147],"predicted":[148,196],"bind":[150],"cut-off":[154],"\u22124":[156],"kcal":[157],"mol":[158],"\u22121":[159],".":[160],"In":[161],"vitro":[162],"isothermal":[163],"titration":[164],"calorimetry":[165],"(37":[166],"\u00b0C,":[167],"pH":[168],"7)":[169],"also":[171],"determine":[174],"enthalpy":[176],"interaction":[178],"18":[182],"most":[185],"clinically":[186,241],"relevant":[187,242],"compounds,":[188],"including":[189],"rocuronium,":[190],"vecuronium":[191],"remifentanyl":[193],"(the":[194],"strongest":[195],"binder":[197],"work).":[202],"All":[203],"had":[204],"low":[205],"injection":[206],"heats":[207],"assay":[209],"parameters":[210],"1500":[212],"\u00b5M":[213,218],"test":[214],"compound":[215],"50":[217],"HP-\u03b2-CD,":[219],"i.e.":[220],"there":[221],"no":[223],"discernible":[224],"HP-\u03b2-CD.":[227],"Thus,":[228],"component":[231],"unlikely":[235],"interfere":[237],"MH.":[244]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2025-10-10T00:00:00"}